CRL furnishes Q3 2025 results; press release dated Nov. 5, 2025

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. furnished an update on its business by issuing a press release with financial results for the third quarter ended September 27, 2025. The press release was provided as Exhibit 99.1 and contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995.

The information under Item 2.02 is being furnished and is not deemed filed under the Exchange Act, except as expressly incorporated by reference in future filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001100682false00011006822025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 5, 2025

Date of Report (Date of earliest event reported)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-15943			06-1397316
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

251 Ballardvale Street

Wilmington, Massachusetts 01887

(Address of Principal Executive Offices) (Zip Code)

781-222-6000

(Registrant’s Telephone Number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.01 par value			CRL			New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02. Results of Operations and Financial Condition

The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On November 5, 2025, Charles River Laboratories International, Inc. issued a press release providing financial results for the third quarter ended September 27, 2025.

The press release, attached as an exhibit to this report, includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press release are "forward-looking" rather than historic. The press release also states that these and other risks relating to Charles River are set forth in the documents filed by Charles River with the Securities and Exchange Commission.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.						Description
99.1						Press release dated November 5, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Date:			November 5, 2025			By:			/s/ Matthew L. Daniel
									Matthew L. Daniel, Corporate Senior Vice President,
									General Counsel, Corporate Secretary & Chief Compliance Officer

3

FAQ

What did CRL disclose in this 8-K?

CRL furnished a press release with financial results for the third quarter ended September 27, 2025, under Item 2.02.

When was the CRL press release issued?

The press release was dated November 5, 2025.

Which exhibit contains the financial results for CRL?

Exhibit 99.1 contains the press release with the third-quarter results.

Are the Item 2.02 disclosures for CRL considered filed?

They are furnished and not deemed filed under the Exchange Act, unless specifically incorporated by reference.

Does the CRL press release include forward-looking statements?

Yes. It includes forward-looking statements with safe harbor language under the Private Securities Litigation Reform Act of 1995.

What period do CRL’s results cover?

The results cover the third quarter ended September 27, 2025.